Mark Scallon, Senior Principal, Commercial Compliance, IQVIA
As regulatory changes continue in the EU and the U.S., life sciences companies will need to focus more on rigor and reproducibility with respect to non-clinical, pre-clinical, clinical data, and post-market data, in addition to the subsequent documentation and audit challenges.
In this blog from IQVIA (originally published November 26, 2018), read how in light of constant changes in requirements and the increasing data needs for compliance, many life sciences companies are embracing technology as the way to transform their decision making, and to streamline and manage the ever-evolving requirements. No matter where your organization falls in GxP, technology is the key to keeping up with the ever-evolving regulatory landscape.
Planning for the New European Regulatory Environment
This brochure from IQVIA outlines the key elements to both the Medial Device and IVD Regulations, and more.